DocGo Inc. (DCGO) Earnings Call Transcript & Summary
November 9, 2026
Earnings Call Speaker Segments
Mike Cole
executiveThank you, operator. Before I hand things over to management, I'd like to offer a few comments about forward-looking statements. Everything discussed on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar expressions may be used to flag these forward-looking statements. Such forward-looking statements do not guarantee future performance, and we cannot assure you that our plans, intentions, outcomes, results, or expectations will be achieved or realized. Statements about the future come with built-in exposure to meaningful risks, unknowns, and presumptions—lots of which we can't control and which might make what we actually achieve, or when we achieve it, diverge substantially from anything such statements describe. Among those risks, unknowns, and presumptions are the ones covered in the risk factors section and other places in DocGo's Form 10-K annual report, its Form 10-Q quarterly reports, the earnings release we issued for this quarter, and additional filings and documents DocGo has submitted to the SEC—all of which deserve your review. What really happens, and when it happens, could end up substantially different from whatever these forward-looking statements say or suggest. This call will also discuss certain non-GAAP financial metrics. You can find reconciliations of those non-GAAP figures to the closest comparable GAAP figures in our earnings release and in the Form 8-K current report that contains the release — both available on our website, docgo.com, and filed with the SEC. The information contained Good afternoon, everyone, and welcome to DocGo's third quarter earnings call. All lines are currently in listen-only mode. Following the presentation, we'll open things up for a question-and-answer session. If you require immediate assistance at any point during the call, just press *0 to reach the operator. Today's call is being recorded on Monday, November 9th, 2026. I'll now pass things along to Michael Cole, our Vice President of Investor Relations. Go right ahead, sir. Thanks, operator. Right now, I'm happy to hand the call over to DocGo's CEO, Mr. Lee Bienstock. Lee, the floor is yours.
Lee Bienstock
executiveThank you, Mike, and thanks to everyone for being with us today. There's plenty to discuss on this call. To start, Norm and I will walk through the operational specifics, and after that I'll address the CEO transition. I'm happy to say that today we're reporting substantial headway on the road to profitability. During the quarter, revenue came in at $73.4 million, and our adjusted EBITDA loss was $3.2 million, versus losses of $6.3 million in the second quarter and $10.2 million in the first quarter, with revenues holding fairly steady. We reaffirmed our full-year 2026 adjusted EBITDA outlook today — a loss ranging from $17 million to $22 million — and we lowered revenue guidance to approximately $300 million, compared with the earlier range of $305 million to $310 million. The revision to revenue reflects the steps we're taking to optimize the business, including restructuring or shutting down lines that aren't profitable. We expect those actions to continue through the fourth quarter and into next year, since our focus is on profitability and cash flow first. With profitability remaining a key priority, I'd like to walk through the primary drivers in revenue, gross margin, and SG&A. To begin, revenue of $73.4 million was roughly flat on a sequential basis, as growth in certain areas offset the effect of eliminating unprofitable revenue streams and optimizing existing operations. We are in the process of winding down our medical transportation business in upstate New York, which brings in about $10 million in annual revenue. I'll get into the financial benefits shortly, but we see this as an important step toward profitability. We've also discontinued or restructured certain care gap closure programs inside our care in the home business, which contributed to a modest revenue decline in the third quarter. Although home-based care is projected to lose roughly $5 million in 2026, the unit's profitability has gotten much better. On a contribution basis, we anticipate this business will achieve positive adjusted EBITDA in late 2026 or the first part of 2027, and we also expect considerable revenue growth in 2027. Home-based care remains, in our view, a central element of our vertically integrated, differentiated care delivery platform — a holistic offering that serves the needs of our healthcare partners and their patients by providing virtual care where it is efficient and in-person care where it is required. Our plan is to continue expanding this model with disciplined growth and a focus on profitability. Also, our gross margin rose to 33.3% during Q3, compared with 30.5% in the immediately preceding quarter. We achieved that gain even though fuel expenses stayed high because of geopolitical developments; those costs trimmed consolidated gross margin by roughly 38 basis points versus the same period a year earlier, when fuel was cheaper. Although most of the markets we've entered have performed well, a handful failed to clear our profitability thresholds, so we're closing down or reorganizing those particular operations. As mentioned before, we're closing our medical transportation business in upstate New York. Without that market, consolidated gross margin would have come in 140 basis points greater. Beyond the favorable effect on gross margin from shutting down operations in that market, we also anticipate it will account for roughly $3 million in adjusted EBITDA loss during this year, which will not recur in 2027. Moving on, adjusted SG&A came down to $28.7 million in Q3, versus $29.7 million in Q2 and $30.8 million in Q1. Part of that gain came from the sizable corporate workforce cut we carried out in June. Further headcount reductions in September ought to help drive more improvement in Q4; on top of that, we are seeing the financial benefit of vendor renegotiations finished earlier this year and keep harnessing AI's advantages to boost operating efficiencies throughout the company. One illustration is the rollout of automated outreach through AI voice agents for our in-home visits, which has cut the cost per booking by more than 50%. Now on liquidity, our cash burn is getting better as well. Unrestricted cash stood at $19.1 million on September 30th, up against $25.2 million at the close of Q2. As Q4 began, we completed the first tranche of our debt facility with Perceptive Advisors, amounting to $12.5 million. Another $12.5 million becomes available when the Hicuity Health transaction closes later this year, and a further $25 million is accessible provided we maintain $130 million in mobile health revenue. To put that in perspective, mobile health revenue, Hicuity included, is currently above $150 million. Our aim is to keep borrowings under this facility to a minimum as we keep moving toward profitability. Alongside lowering operating cash burn, we are advancing considerably in collecting long-outstanding receivables tied to our discontinued municipal population health business. There are two major receivables totaling about $19 million, and we have made substantial headway on each. The smaller one comes to roughly $6.7 million, most of which we anticipate collecting very soon. The remaining receivable, at $12.6 million, will probably be settled late this year or early in 2027. All told, these developments show considerable gains in both liquidity and profitability, and I stay optimistic that such trends will carry on. Our commitment to reaching a profitable run rate by year-end remains firm, and we continue to make substantial progress toward that goal. With that said, I'll hand it over to Norm, who will walk through the financial details.
Norm Rosenberg
executiveThanks, Lee, and good afternoon, everyone. For the third quarter of 2026, total revenue came in at $73.4 million, which is a 4% rise from $70.8 million in the third quarter of 2025. That marked our first year-over-year revenue increase since the second quarter of 2023 — an important milestone that we think shows the progress we've made in repositioning the business for growth. For context, the third quarter of last year contained $8.4 million of migrant-related revenue. If we take that revenue out of the 2025 comparison, third quarter revenue rose 18% year-over-year. That gain was mostly driven by SteadyMD, which we acquired in October 2025 and which added $7.8 million of revenue in the third quarter of 2026. If we exclude both the migrant-related revenue in the 2025 period and the SteadyMD revenue in the 2026 period, revenue was still up roughly 5% year-over-year. Medical transportation services revenue hit $53.3 million in the third quarter of 2026, an increase of 6.4% from $50.1 million in the third quarter of 2025. That topped the second quarter's transport revenue and set a new quarterly record for DocGo. The growth came from both large and small US markets, with some of the strongest gains in the New York City market, in Delaware, Wisconsin, and Tennessee; we keep seeing rising demand across most of our markets. Mobile health revenue was $20.2 million in the third quarter of 2026, with no contribution from migrant-related revenue, versus $20.7 million in the third quarter of 2025, which included $8.4 million of migrant-related revenue. To be specific, non-migrant mobile health revenue grew 64% year-over-year; that growth reflected gains in remote patient monitoring and mobile phlebotomy, along with revenue from SteadyMD, which we acquired during the fourth quarter of 2025. Adjusted EBITDA for the third quarter of 2026 was negative $3.2 million, compared with negative $7.2 million in the third quarter of 2025. Adjusted gross margin, which strips out the impact of depreciation and amortization and is the margin measure we follow most closely, was 33.3% in the third quarter of 2026, versus 33% in the third quarter of 2025. In the third quarter of 2026, adjusted gross margins from the medical transportation segment were 34.7%, versus 31.7% in Q3 of 2025, and up solidly from the first two quarters of this year. We made significant strides in raising our field headcount in the first half of 2026, and the overtime rate declined again in the third quarter of 2026 to near 10%, which is well below the nearly 14% we saw throughout much of 2025. Even with that strong improvement, medical transportation gross margins are still held back by a couple of factors. First, we're still seeing higher than expected fuel costs. Our average gas price was $4.18 per gallon in Q3, a slight decrease from $4.27 in Q2 of 2026, but more than a dollar per gallon above last year's third quarter. According to our estimates, higher fuel costs held back transport gross margins by roughly 52 basis points compared with a year ago, and they held back the consolidated gross margin by roughly 38 basis points. Second, transport gross margins felt the effect of persistently weak performance in the upstate New York market, and there we have started the process of winding down operations, leaving that market, and selling our license. If we set the upstate New York market aside from our results, we estimate third quarter medical transportation gross margins would have come in near 37%. For the mobile health segment, adjusted gross margin stood at 29.7%, compared with 36.2% in the third quarter of 2025. SteadyMD's gross margins ran several points below normal, a reflection of aggressive hiring through the year-to-date to catch up with greater demand from large customers and in anticipation of substantially higher seasonal volumes in the fourth quarter. That said, SteadyMD's gross margins rose in each month of the third quarter and arrived at a much more normalized level in September, which points favorably toward improvement in the fourth quarter. The drag from SteadyMD's below-par margins was partly offset by larger relative contributions from other service lines with higher margins, including remote patient monitoring and mobile phlebotomy. Beyond the gross margin expansion we saw this quarter, recurring operating expenses fell once more as anticipated; the reason was the cost-cutting actions put in place so far this year, mainly in headcount and vendor spending. Working against that effect were higher recruiting costs stemming from stepped-up hiring, onboarding, and training of EMTs and mobile health clinical staff to meet customer demand. In the third quarter, we spent roughly $200,000 on recruiting outreach, which supplemented the work of our in-house recruiting team. With SteadyMD's latest hiring push largely behind us, our ongoing cost-cutting efforts during the first half of 2026, and further savings still to come from our efficiency portfolio initiative, we expect SG&A to keep declining sequentially over the coming several quarters. We now expect full year 2026 revenue of approximately $300 million, as Lee mentioned earlier and as we said in our press release. That is a bit under our most recent guidance range of $305 million to $310 million, though it sits at the higher end of our initial guidance range of $280 million to $300 million. The revenue outlook leaves out any revenue from the Hicuity Health acquisition, which we expect to close later this month or early next month. Our adjusted EBITDA outlook has not changed. We still anticipate a full year adjusted EBITDA loss of between $17 million and $22 million. Last, on the balance sheet, as of September 30th, 2026, available cash was $19.1 million, lower than $25.2 million at June 30th; on October 1st, immediately after the third quarter closed, we completed the first $12.5 million tranche of funding from the Perceptive term loan, which has raised our available cash balance. The term loan commitment we've secured from Perceptive — which takes the place of our asset-based credit line — is going to reshape our balance sheet right away, giving us both the flexibility and the security required to carry out our growth plans. Looking further ahead, we'll keep exploring and carrying out whatever steps are needed to reposition our portfolio of business lines and to make our balance sheet stronger, so the company becomes leaner and more profitable. With that, I'd like to hand the call back to Lee for a few closing remarks.
Lee Bienstock
executiveThanks, Norm. For me, today brings a blend of feelings, though pride is the dominant one. We announced today that once my successor is appointed, I will be stepping away from my position as CEO of DocGo, and I'd like to explain why I feel so positive about the state we're in; our effort has gone into pivoting DocGo away from being a company rooted in emergency response and toward becoming a vertically integrated hybrid care company. As things stand today, we bring together medical transportation, virtual care, in-person care, and proprietary technology in order to serve millions of patients throughout the whole healthcare continuum, from the hospital to the home. During the past three years, we have steered through executive transitions and significant changes in our government business. PTI, SteadyMD, and Hicuity Health were brought into the DocGo family by us so that our virtual and in-person care could expand. We kept executing and growing our medical transportation and mobile health offerings, producing hundreds of millions of dollars in evergreen healthcare revenue, and we gained the trust of an impressive roster of blue-chip healthcare partners. Change hasn't merely been weathered by our company; we have harnessed it to build something stronger, and the fruits of those efforts are beginning to appear. We have just posted our strongest EBITDA performance since Q4 2024, and we remain on track to exit 2026 at a profitable run rate as well. When I assumed this role, setting the vision and building the foundation was my task. That foundation now exists, and I hold a strong conviction that the company is headed in a positive direction. My belief is firm that DocGo is positioned to generate significant value as healthcare keeps evolving, and I will be cheering this team on at every step. My plan is to remain until at least March 31st, 2027, and I will coordinate closely with the board toward an orderly transition; during that interim period, my full focus will stay on driving our profitability, cash flow, and growth. Our valued customers, our committed employees, and our stakeholders have always ranked as my top priority, and that will not change. Leading and working beside our staff of thousands of healthcare heroes has been an honor, and my gratitude for their dedication, their resilience, and all they have given to this company and our patients is endless. Thank you. With that, I would like to hand the call to the operator for Q&A. Operator, please go ahead.
Pito Chickering
analystHello, good afternoon everybody, and I appreciate you taking my questions. Lee, I'd say thanks for all the help you've given and I wish you the best ahead. So I guess my first question is: since you're concentrating on profitability as you exit the year, is there any guidance on how we ought to think about revenue growth and EBITDA growth for roughly 2027, given that you're stepping up your EBITDA guidance in the fourth quarter to what I believe is full break-even?
Norm Rosenberg
executiveHi, this is Norm. I'll handle that question. We deliberately chose not to provide 2027 guidance on today's call. Historically, I'm aware that at times we've issued it during our first call of the calendar year, and at other times we've done so on the final call of the year—which is what this one would have been. Clearly, with the CEO transition currently in motion, or soon to begin, that adds some complication. Even so, we have worked through our budgeting process—we're far along in it, and I can share a few details. We definitely anticipate meaningful revenue growth compared with last year. Our medical transportation business keeps expanding at what I'd characterize as a high single-digit rate. Nothing in that area would truly alter it, except—as we noted—the upstate New York market might be reduced in scale, though growth across several of our bigger markets will more than compensate and outweigh that. That should produce some expansion. All remaining parts of our mobile health business will keep expanding and are set to expand compared with the prior year. When you look at mobile phlebotomy or remote patient monitoring, clearly on the care-in-the-home side we're being pickier about which business we accept, and growth will be somewhat more moderate, though we should certainly still see year-over-year gains in each of those business lines. I believe you'll see genuine growth pretty much everywhere. That applies to SteadyMD as well, and of course we add Hicuity Health next year, which will grow too—but relative to what you'll see in 2026, that's largely going to be entirely incremental revenue. Regarding margins, the initial priority in my view is ensuring the improvements achieved this quarter can be sustained. When we examine these line items—and as I noted, certain factors actually shifted adversely for us that we expect to ease, like fuel prices, which will ultimately decline and should provide a modest tailwind. Even more significant, as we exit or restructure markets—transport markets come to mind—that presently deliver below-average margins, we believe a greater margin level is attainable. On the transport side, every one of our core markets is running at margins that meet or beat plan, and we should see that carry on. Then last, when it comes to operating expenses, we've devoted substantial time and effort to extracting everything we possibly could there. More can still be done down the road. That will matter to us as well. Putting all of it together, we'd anticipate reporting a positive EBITDA figure. I realize that's an extremely wide range, since I'm not providing a specific number, but across the full year 2027, we expect to deliver some positive EBITDA along the way, alongside fairly substantial growth over the prior year on the top line.
Pito Chickering
analystFair enough. So turning to Michael, now that you're beginning the hunt for a replacement CEO, which capabilities are you seeking in that person, and ought we to anticipate any strategic shifts down the road? Oh,
Michael Burdiek
executivewell, thanks for asking, and it's good to talk with you today. It's a bit melancholy, clearly, given the word of Lee's exit coming up here. Lee possesses some remarkable talents, and I'm certain he'll locate a suitable home for those talents later on, very confident about that. Both the board and I want to thank him for what he has contributed so far and through the coming few months as we look for a successor. Clearly, we're entering a different stage in the life of the company; we've gone through considerable restructuring, a couple of significant acquisitions lately. As Lee noted, we've built a new foundation for the company, and I think operational capability along with operational leadership abilities — someone who has, in effect, already done it when it comes to restructuring and turnaround work previously would likely be a good sort of checklist to tick off for prospective candidates. We're simply after a strong leader. We're moving into a new stage for the company, and we're seeking something of a fresh start.
Pito Chickering
analystFair enough. So one last question for Norm. If you look at the revenue guidance implied for the fourth quarter, it seems to be up roughly $4 million. Medical transport has been growing pretty steadily all year, but I think that should come under some pressure as you wind down New York, and on the mobile health side, you're winding down some of the less profitable areas. So how should we be modeling that $4 million of sequential revenue growth in Q4, given the New York pressure on medical and then the reduction in some of these home visits on the mobile side? Thank you.
Norm Rosenberg
executiveSure. Good question. Honestly, this may be the first time — I've been with the company several years, and folks constantly ask whether our business has seasonality, and my answer has always been that we're growing quite quickly and seasonality doesn't play a role, but now I need to tell you a seasonal factor really will be present in Q4. SteadyMD traditionally brings in considerably more revenue during Q4. Judging by the backlog and the work we know they've signed, things are looking that way; they posted roughly $7.8 million, call it $8 million, in Q3. I'd expect that figure to come in a solid couple million or so above that in Q4. That will contribute to the gain. Regarding home care, that business remains far more seasonal in nature compared with what they can accomplish during Q4, so that will account for part of the driver; and on the transport side, we're already nearly midway through the fourth quarter; volumes have kept climbing on a sequential basis, whether in New York City, our primary market, or even in the UK or other similar places; when we consider what would be required to reach roughly that $300 million level, we believe the implied revenue for the fourth quarter would land somewhere around $77 million to $78 million or thereabouts. Right now, that seems like a goal well within our reach.
Lee Bienstock
executiveI'd like to add something, Pito — and thanks for the kind words; this is Lee. On the care in the home business, we did pull back on that during the quarter as we reduced our outreach activities and worked on strengthening our go-to-market model. That work was completed in Q3, and we anticipate growing the care in the home business in Q4 and beyond under this new unit economic model we've managed to put in place, changing the kind of clinician we have in the field. We finished that effort in Q3, and we're looking to scale that care in the home business under this new unit economic model in Q4, and then, naturally, it's a significant quarter for us seasonally, and then on into 2027 as well.
Pito Chickering
analystGreat. Thanks so much, guys.
Lee Bienstock
executiveThank you, Pito.
Matt Shea
analystHi, Matt Shea here, filling in for Ryan. Appreciate you taking our questions. It was a pleasure working with you, Lee. Best of luck with whatever comes next. I'd like to begin with the commentary about dialing back. First, Lee, you brought up restructuring some of the care in the home programs. I'm not sure whether I caught it, but which programs or areas are shifting the most? Is it mostly the unit economic model? Then, stepping back, you discussed dialing back patient outreach and clinical operations in order to prioritize profitability, yet you also announced that new program in Pennsylvania. Does that Pennsylvania relationship involve any in-home care components, or what's the right way to read it? Is this purely about optimizing the portfolio, and what makes Pennsylvania attractive relative to the core regions you're exiting?
Lee Bienstock
executiveFor sure. Appreciate it, Matt — same here, it's been a pleasure getting acquainted and collaborating with you. Regarding the in-home care business, we did mention that our visit volume declined roughly 26% during Q3, and that was fully intentional. Essentially we took two steps. First, we scaled back our outreach activities. The people on our team who contact patients to arrange appointments, verify them, and coordinate them — we optimized a great deal of that work in the quarter using AI. As I said in the prepared remarks, we've been rolling out AI efficiency programs that let us handle this at a much lower cost; we pulled back on it while developing the AI efforts that will now let us expand it far more profitably. That was the first step we took on AI optimization and the outreach side; the second step we took during the quarter involved changing the mix of clinicians we have in the field. In the past, our field staff consisted solely of LPNs—licensed practical nurses—supervised remotely by licensed clinicians through telehealth. We have now changed that composition to include not just LPNs but mobile phlebotomists and medical assistants as well. This has let us expand our operations while achieving greater cost efficiency. Much of that transition was carried out during Q3, and we expect it to pay off in Q4 and beyond. What drove that was really a combination of efficiencies we gained in the field plus back-office automation — specifically around outreach — and that's what will let us grow this at better margins. During the quarter, we scaled back visits while putting those changes in place, so that heading into Q4 and 2027 we can expand with those optimizations already working. That was truly the major shift, and it will extend into the new initiatives we plan to launch in Pennsylvania. The same model I just walked through — the one that got our unit economic cost down — will be applied in Pennsylvania as well. Another positive is that our medical transportation business has solid operations in Pennsylvania. Our mobile healthcare teams will launch from the very same Pennsylvania sites where we serve medical transportation customers. We'll provide this for a major national payer in the Pennsylvania market; we're drawing on efficiencies wherever we can together with our other businesses, including medical transportation, and also changing the mix in the field and in patient engagement so we can lower cost and scale more profitably, and that's the effect you're seeing from the quarter, setting us up for next quarter and beyond.
Matt Shea
analystUnderstood. That's really useful, Lee. So then perhaps regarding the physician fee schedule, it looked like there were a few favorable changes at least on your end when it comes to RPM, and it appeared that whatever requirements they set going forward would fit nicely with your model, but I'm curious what your pluses and minuses were from the physician fee schedule and maybe just a thought on how you're viewing RPM.
Lee Bienstock
executiveSure; regarding the physician fee schedule, so like you said, there are a few steps forward and changes really at CMS where they're essentially mandating a physician visit, a well visit, in order to be enrolled in RPM. You just can't sign up a patient unless there's also a medical visit. As you point out, we not only furnish the medical visits, we also furnish the patient monitoring, so we're capable of doing both, and we believe that's an advantage for us and a positive, and likewise a solid plus for the patient. On the patient monitoring front, the main codes we bill for the services we deliver are chiefly for the cardiac implantable devices such as pacemakers and loop recorders; those fee schedules have stayed pretty much the same; they're clearly quite important for patients with heart failure to be tracking a patient's heart rhythm routinely and in real time, and so we feel we're in a strong position there. I'd add as well, the changes you brought up, where we're able to deliver RPM services while also delivering the medical care that comes along with it, is likely the direction the industry is moving, and we're set up very well for that.
Matt Shea
analystGreat. Thanks, guys.
Lee Bienstock
executiveThanks, Matt.
Richard Close
analystThanks for the questions, and Lee, best of luck in what's ahead — though I gather you'll still be around through March. Maybe I can pick up where Pito's questions left off and take them a bit further. On the updated revenue guidance for '26, Norm, it sounds like New York accounts for roughly $10 million in annualized revenue, and if we assume you shut that down at the start of the quarter, that's around a $2.5 million impact on the updated guidance. Could you tell us what the remaining $2.5 million relates to? That would be helpful.
Norm Rosenberg
executiveFirst thing to note is that it isn't — the shutdown is more gradual than people are expecting; we're still running some traffic, and that will wind down. It won't come anywhere close to a $2.5 million drop quarter-over-quarter. In fact, it had already begun dipping somewhat in Q3 compared with Q2. That impact will probably be, I don't know, maybe half of that — maybe $1 million, $1.5 million, as we go. There are still contracts we continue to honor and need to honor, and there's still traffic we need to take. You can't simply stop taking those trips all at once. That's something that will have a full-year impact over a longer stretch, but less of an impact in the fourth quarter; then as for your question about the other $2.5 million, I'm not sure what you were asking.
Richard Close
analystIf New York were going to come in at $2.5 million — which it isn't — I'm just trying to think through guidance moving from $305 million — Oh,
Norm Rosenberg
executiveoh, the guidance decline. Sure. I'd describe it as a combination of factors. As we worked through the numbers and considered a full year of SteadyMD, I'd say perhaps SteadyMD comes in a shade lower than — and I'll tell you, obviously, since it's a fairly new business for us, when we initially acquired it, we made certain assumptions about what they'd do in 2026, and we quickly, or rather sharply, raised that expectation as the first couple quarters came in, and now we've likely pulled it back somewhat. Q3 revenue is probably, I don't know, half a million to a million dollars below what we'd have expected, and for the full year, that's probably around a million, a million and change. Then on the care in the home side as well, roughly a similar amount is coming in somewhat lower. Looking at the other business lines, like our flagship New York City transport market, it's basically hitting all the figures we had expected them to hit, maybe even slightly above. The same holds for most of the transport markets. When I look at things such as mobile phlebotomy and the CRMS business, the remote patient monitoring business, I think that business too is really performing right in line with our expectations. That $5 million figure — it's a million here, a million there, and a couple million there, is really what it boils down to.
Lee Bienstock
executiveI'd like to add something to that, Richard. We truly took an intentional approach to either terminating contracts — even in certain markets performing well — but terminating agreements that weren't profitable for us, or scaling back some hiring initiatives to ensure that, once again, we're meeting those profitability targets. We genuinely made an effort to either close or restructure both markets that weren't performing, and also certain contracts we held in markets doing well, but again, that were dragging on profitability. That was the balance we achieved, which was essentially surrendering some revenue, so to speak, again, falling a little short on revenue, but boosting margin considerably, which we witnessed in the quarter. That was an intentional choice, and that's essentially what we carried out in the quarter and have continued carrying out since, as we're now in Q4.
Richard Close
analystAll right. Now regarding, I suppose, what was said about the $300 million of revenue and the $240 million that's profitable — the $60 million that isn't — it sounds as though a decision is coming by year-end if profitability isn't reached there. I'm just trying to get a sense of where that $60 million falls between transportation and mobile, and then perhaps how much of that $60 million is fairly near positive adjusted EBITDA on a contribution basis.
Lee Bienstock
executiveSure. First, on the $60 million — which, I believe you said we've disclosed — $240 million out of the $300 million contributes positive EBITDA. We do have $60 million that is a drag on margin. Of that $60 million, roughly one-third is what we'll shut down. As we mentioned already, the upstate New York market. Also, we have a few more contracts in the UK, plus some work here in the US again on the mobile health side where those contracts aren't accretive, so we're going to wind those down. That's roughly a third of the $60 million, again. For two-thirds of the $60 million, we think we can restructure it effectively, either by going back over the contracts we hold — some legacy contracts of ours that are more than five years old; for many months we've been working to evolve those contracts and renegotiate the rates in them, and I believe that will pay off as we exit this year and move into next year. Roughly two-thirds of that $60 million, we believe, will be restructured or renegotiated in a way that lets us produce EBITDA from those contracts and service lines and markets. Within those two-thirds, again, it's a mix. Some medical transportation is in there; some virtual care and care in the home is also in that two-thirds, but on the whole we feel two-thirds of it can be evolved and restructured so that it contributes EBITDA next year.
Norm Rosenberg
executiveI'd like to build on that point: by the time we closed out the third quarter, sizable portions of that $60 million basket had already turned positive during the later part of Q3. One illustration: some of the gross margin gains we recorded comparing Q2 with Q3, or on a year-over-year basis, came from the Pennsylvania-New Jersey market — one of our largest markets, likely our second-biggest US-based transportation market, and a notoriously difficult one — yet we were benefiting from a fairly low comp, and that market finished the quarter posting gross margins in the low to mid-30s, which is quite healthy; we always want more, of course. Still, looking at September alone, for instance, it contributed positively to EBITDA. I won't claim the problem is solved; clearly it's a continuing fight to ensure we can hold that margin level, but this is somewhere you reach, as Lee noted, through managing your portfolio of varying contracts, varying customers, and volumes, and a genuine pathway exists to get there. This isn't a fundamentally broken market where nobody can earn money; it's one where earning money is possible provided you can be compensated properly — or rather reimbursed properly — for the cost of delivering that service. By contrast, other markets we've tried a few times and found to be inherently not truly profitable, and over the years those have included places such as California and Colorado; these days we discuss the upstate New York market. None of this is new. It's really a pruning exercise we've carried out for years now, but much of that $60 million, if I were looking at it today, already sits on the positive side of the ledger.
Richard Close
analystThat's useful. I suppose my last question is just for an update on anything happening with Hicuity? Has that deal slipped somewhat, or is there anything you can tell us there that would be good.
Lee Bienstock
executiveFor sure. There's no slippage at all. A regulatory approval is what we've been waiting for, and so we've been saying that we expect to close that transaction at the end of this month, and we're on track to do so.
Richard Close
analystThank you.
Lee Bienstock
executiveOf course. Thank you.
David Larsen
analystHello. Lee, excellent job during your time at DocGo. You'll certainly be missed, and I believe you built a solid foundation for the business. I suppose could you separate out the revenue pieces for fiscal '26 across mobile phlebotomy, monitoring, care gaps, and SteadyMD? What revenue is expected in '26 from each of those four areas, and do you have any indication of the growth rate? Thanks.
Lee Bienstock
executiveThanks very much, Dave, and I appreciate those kind remarks. First of all, I'd say that out of the $300 million, roughly $205 million to $210 million will be derived from medical transportation across the year, as we expect, and the rest will be generated by mobile health. Once more, no contribution from Hicuity is included here, since that deal hasn't closed yet, so whatever they might add would come on top of this. Norm will go into the revenue components of your question in a bit more detail.
Norm Rosenberg
executiveLet's walk through these, and of course I'm rounding a bit here. On the remote patient monitoring side, we're probably looking at roughly $16 million to $17 million. For SteadyMD, we think it'll be in the low 30s — I'll say somewhere between $30 million and $35 million, probably around $33 million. Mobile phlebotomy for the year should land between $5 million and $6 million. Clinical staffing should come in at about $14 million, $15 million for the year. I'm not sure whether I'm forgetting anything here. Oh, and care in the home — I'm not sure where that number will land, probably also in the $7 million or $8 million range, maybe even as much as $9 million, depending on the seasonality gains we get in the fourth quarter.
David Larsen
analystIn that press report, you pointed out a few growth rates — honestly, all of them looked quite strong to me. So I suppose my question is, where exactly is that low or absent growth coming from?
Lee Bienstock
executiveAre you referring to the mobile healthcare or the medical transportation?
David Larsen
analystMobile.
Lee Bienstock
executiveTurning to mobile, once more, we have been extremely, extremely intentional — starting with care in the home. As I said, we had projected a stronger growth rate for care in the home, yet we were quite intentional about trimming that back during Q3. Once more, we cut volume there by 26%, which benefited margin but clearly took a toll on the top line; beyond that, we have taken a very, very measured stance toward certain of the clinical staffing efforts we pursue on the growth side, and even regarding the remote patient monitoring growth within the business. Our priority this year has been profitability, and once again, those results showed up in the quarter, and we anticipate that continuing — but this year we put profitability and margins ahead of growth. Even in medical transportation, once more, we have been reducing some staffing in favor of margins. That is genuinely what we placed first across this year as we also move toward next year.
Norm Rosenberg
executiveFor next year, I'd say we're likely to shift things somewhat, in that our focus will be a bit less concentrated — right, transportation revenue has two parts: volume, and then the average price per trip. We've been extremely focused on the volume side, since we're working to build market share and to grow volumes with certain specific large customers. In 2027, we're going to put considerably more thought and effort into portfolio management; you might see some pulling back on those volume gains — they'll still be up, but the increase will be smaller — and a much greater emphasis on having the right mix. When we look at a market, should we have the mix we have of the different types of payers? Should we have the mix we have of the certain type of traffic, for example, basic life savings versus advanced life savings, critical care — and trying to do that in a way that lets us maximize the price that we're paid for each trip. I think that'll be somewhat more of a point of emphasis in 2027.
David Larsen
analystThat's excellent. So ahead of year-end, how much additional cost do you expect to remove from the business, and when do you anticipate reaching positive cash flow? Could you also remind me of the cash flow figure for the quarter, what you expect it to be in 4Q, and what you expect in '27?
Lee Bienstock
executiveI'll hand the cash flow part of that question to Norm. On the cost-cutting side, I think we've said previously that our profitability model is roughly $80 million of revenue, gross margin around the mid-30s, and SG&A of about $28 million; that brings us to break-even. In the quarter — this quarter we just reported — I think we demonstrated that we're nearing the mid-30s level on gross margin, and SG&A came in at $28.7 million, really close to that $28 million mark. Over the quarter, I think you're going to see revenues grow in Q4. As Norm mentioned, it's our strongest seasonal quarter on medical transportation and mobile health, and I think you'll see us reduce SG&A further beyond the $28.7 million where we stand today, but we're very near that $28 million target, though we believe there's more opportunity there. Then again, we want to drive the margin — the gross margin — higher. As Norm shared, excluding the upstate New York market, our transportation gross margin would have come in at 37%, which, I know, Dave, you follow our business closely, that is a significant, significant improvement from where we've been on gross margin. I think it truly is a combination of all these factors. We're going to push revenue up in the quarter as we add the seasonal volume that we see in Q4. I think there's further opportunity for us to improve gross margin, which we showed significant progress on in the quarter. Again, we're right at that $28 million of SG&A, quarterly SG&A — we were at $28.7 million for the quarter — and we think there's additional opportunity to cut from there, and we've been working toward that.
Norm Rosenberg
executiveNow on cash flow — if you look at operating activities for the nine-month stretch, we were lower by roughly $18 million. During the quarter itself, that figure came in at just about $3 million or $4 million. That's clearly a — those are the numbers on the cash flow statement, and we got there without seeing AR fall very much, correct? Collections are usually something we handle reasonably well, but we didn't see any of those sizable bulk payments of aged receivables from New York City or anywhere else in the third quarter; as Lee mentioned in his remarks on this call, we definitely anticipate a solid chunk of that arriving in Q4, and whatever doesn't arrive in Q4 would, we hope, arrive in Q1 of '27, but none of that affected us during the three months ended September 30th; we actually managed that burn fairly well. Looking just at the headline cash figure, available cash stood at $19 million when the quarter closed, compared with $25 million when the second quarter closed. If you look at those raw figures and consider where we stood, say, in Q1 or Q2, or even at the close of last year, you've witnessed a burn that keeps declining. The burn rate, say, during last year's fourth quarter came to roughly $22 million, if you simply compare available cash at the start and the end of that quarter. That fell to $15 million in Q1. During Q2, available cash declined by $10 million; in Q3, the decline shrank to $6 million. There's no pure mathematical rule that guarantees that figure will be far lower, but those are the trends and those are the things we're observing; we're observing that cash flow, or negative cash flow, is tracking the same pattern as the EBITDA burn, or the negative EBITDA figure, coming down; we do expect that to happen. That said, I would note that because of some of the payments we have to make, we might reach positive cash flow from operations perhaps a quarter or two after we reach that level on the EBITDA side. If, for instance, we manage to hit EBITDA break-even or slightly positive in Q4, I think it may not be until Q1 or perhaps even Q2 that we post positive operating cash flow, depending on how the receivables come in.
David Larsen
analystThanks very much.
Lee Bienstock
executiveThanks, Dave.
Lee Bienstock
executiveThank you so much, and thank you all for joining. Be well.
Operator
operatorAlright everyone, that brings today's conference call to a close. We appreciate your participation and kindly request that you disconnect your lines now. Have a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.